Merus Labs International Inc. Co (MSLI) 1.28 $MSLI
Merus Labs International Inc. Announces Normal Course Issuer Bid
Marketwire Canada - Mon Nov 17, 7:00AM CST
Merus Labs International Inc. ("Merus" or the "Company"
(TSX:MSL)(NASDAQ:MSLI) announced today that it is proceeding with a normal course issuer bid for up to 7,615,972 common shares of the Company, representing approximately 10% of the total public float of the common shares of the Company. On November 12, 2014, the Company had a total of 81,245,724 common shares outstanding out of which a total of 5,086,000 common shares are non-public shares held by directors and senior officers or held in escrow. The Company has received approval from the Toronto Stock Exchange (the "TSX" to commence this bid on November 19, 2014. Purchases will be made on the TSX at the market price at the time of acquisition. Pursuant to TSX policies, daily purchases will not exceed 149,025 common shares except where such purchases are made in accordance with "block purchases" exemptions under applicable TSX policies.
MSL.TO: 1.46 (+0.04), MSLI: 1.28 (+0.03)
Merus Labs International Inc (MSLI) Downgraded From Hold to Sell
at The Street - Tue Oct 28, 8:46AM CDT
Merus Labs International Inc (MSLI) has been downgraded by TheStreet Ratings from Hold to Sell with a ratings score of D+.
MSLI: 1.28 (+0.03)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Oct 15, 11:47AM CDT
NPD: 1.38 (-0.03), IMDZ: 22.35 (-0.20), BCRX: 10.06 (+0.02), DLHC: 2.34 (-0.04), SWSH: 1.68 (-0.02), VSR: 2.99 (-0.03), PPHM: 1.48 (-0.01), EVRY: 0.76 (+0.03), DYNT: 3.81 (unch), NBG: 1.79 (-0.01), AMDA: 0.69 (-0.01), TRCH: 0.85 (-0.04), KTCC: 7.98 (-0.12), APT: 2.64 (-0.03), SHPG: 213.70 (-0.41), PENX: 18.90 (+0.01), LAKE: 10.79 (-0.40), MSLI: 1.28 (+0.03), COVS: 2.73 (unch)
Merus Labs Announces Management & Board Changes
Marketwire - Tue Sep 23, 6:31AM CDT
Merus Labs International Inc. ("Merus" or the "Company" (TSX: MSL)(NASDAQ: MSLI) today announced that Mr. Elie Farah has resigned as CEO and as a member of the Merus Board to pursue other opportunities. The Board of Directors thanks Mr. Farah for his contribution to building a strong foundation and platform for growth for the Company and wishes him well in his future endeavors.
MSLI: 1.28 (+0.03)
Merus Labs International (MSLI) Upgraded From Sell to Hold
at The Street - Tue Sep 16, 8:04AM CDT
Merus Labs International (MSLI) has been upgraded by TheStreet Ratings from Sell to Hold with a ratings score of C.
MSLI: 1.28 (+0.03)
IIROC Trade Resumption - MSL
CNW Group - Mon Sep 08, 7:44AM CDT
Trading resumes in:
MSLI: 1.28 (+0.03)
IIROC Trade Resumption - Merus Labs International Inc.
Newsfile Corp - Mon Sep 08, 7:38AM CDT
Trading resumes in:
MSLI: 1.28 (+0.03)
Merus Labs International Inc. Announces Acquisition of Sintrom(R)
Marketwire - Mon Sep 08, 7:32AM CDT
Merus Labs International Inc. ("Merus" or the "Company" (TSX: MSL)(NASDAQ: MSLI) is pleased to announce that one of its wholly owned subsidiaries has acquired from Novartis AG ("Novartis" , in certain European countries, the rights to manufacture, market, and sell the branded prescription medicine product Sintrom(R) (acenocoumarol). Acenocoumarol is an anticoagulant indicated for the treatment and prevention of thromboembolic diseases. Sintrom(R) has been available in Europe for over 50 years and in calendar year 2013 the product had net sales of approximately US$28 million in the territories acquired.
MSLI: 1.28 (+0.03), NVS: 93.52 (-0.82)
IIROC Trading Halt - MSL
CNW Group - Mon Sep 08, 7:17AM CDT
The following issues have been halted by IIROC:
MSLI: 1.28 (+0.03)
Merus Labs International Inc. Announces Completion of $7 Million Financing Transaction With Dacha Strategic Metals Inc.
Marketwire - Thu Aug 14, 2:29PM CDT
Merus Labs International Inc. ("Merus" or the "Company" (TSX: MSL)(NASDAQ: MSLI) is pleased to announce that, further to its news release dated July 4, 2014, the Company has today completed the financing acquisition transaction with Dacha Strategic Metals Inc. ("Dacha" . The Company issued 4,246,544 common shares to Dacha in exchange for all of the issued and outstanding shares of a newly incorporated subsidiary ("Newco" incorporated by Dacha for the completion of the transaction. Newco held $6,975,001 in cash and had no other assets or liabilities upon completion of the Acquisition.
MSLI: 1.28 (+0.03)
Merus Labs International Inc. Subsidiary Signs Product Acquisition Letter of Intent
Marketwire - Fri Aug 08, 5:16AM CDT
Merus Labs International Inc. ("Merus" or the "Company" (TSX: MSL)(NASDAQ: MSLI) is pleased to announce today that one of its wholly owned subsidiaries has signed a letter of intent to acquire the rights to manufacture, market, and sell a branded prescription medicine product in certain European countries. The product is being divested by a large multinational pharmaceutical company. In the calendar year 2013, the product had net sales of approximately US$28 million in the applicable European territories.
MSLI: 1.28 (+0.03)
Merus Labs International Inc. Announces Conversion of $10 Million Convertible Debentures
Marketwire - Thu Jul 17, 3:00PM CDT
Merus Labs International Inc. ("Merus" or the "Company" (TSX: MSL)(NASDAQ: MSLI) is pleased to announce today that the Company has exercised its right to convert the $10 million unsecured convertible debentures (the "Convertible Debentures" issued to a large Canadian institutional investor in September 2013. The Company exercised its right based on the closing price of the Company's common shares having equalled or exceeded $2.30 per share for the 20 consecutive trading days ended July 14, 2014. In aggregate, the Company will issue 6,677,918 common shares to convert the outstanding $10 million principal amount plus accrued but unpaid interest.
MSLI: 1.28 (+0.03)
Dacha releases audited financial statements for year ended March 31, 2014 and provides update on Merus transaction
CNW Group - Fri Jul 11, 3:15PM CDT
Dacha Strategic Metals Inc. (TSX-V: DSM) ("Dacha" today released its audited consolidated financial results for the year ended March 31, 2014 and provided an update on its pending transaction involving Merus Labs International Inc. ("Merus" . For more information, please see Dacha's audited consolidated financial statements and management's discussion and analysis filed under Dacha's profile on SEDAR at www.sedar.com. Unless otherwise noted, dollar references below are to U.S. funds.
DSM.VN: 0.185 (-0.010), MSLI: 1.28 (+0.03)
Merus Labs International Inc. Announces Closing of $10 Million Preferred Share Financing
Marketwire - Fri Jul 11, 3:01PM CDT
Merus Labs International Inc. ("Merus" or the "Company" (TSX: MSL)(NASDAQ: MSLI) is pleased to announce today that the Company has completed its previously announced private placement issuance of $10 million of Series A convertible preferred shares (the "Series A Preferred Shares" to a large Canadian institutional investor. In aggregate, the Company issued 10,000 Series A Preferred Shares at a price of $1,000 per share for total proceeds of $10 million. The proceeds of the offering are expected to be used by the Company for future acquisition opportunities as well as for general corporate purposes. Additional details regarding the Series A Preferred Shares are provided in the Company's June 10, 2014 news release.
MSLI: 1.28 (+0.03)
Merus Labs International Inc. Announces Normal Course Issuer Bid
Marketwire Canada - Mon Nov 17, 7:00AM CST
Merus Labs International Inc. ("Merus" or the "Company"
(TSX:MSL)(NASDAQ:MSLI) announced today that it is proceeding with a normal course issuer bid for up to 7,615,972 common shares of the Company, representing approximately 10% of the total public float of the common shares of the Company. On November 12, 2014, the Company had a total of 81,245,724 common shares outstanding out of which a total of 5,086,000 common shares are non-public shares held by directors and senior officers or held in escrow. The Company has received approval from the Toronto Stock Exchange (the "TSX" to commence this bid on November 19, 2014. Purchases will be made on the TSX at the market price at the time of acquisition. Pursuant to TSX policies, daily purchases will not exceed 149,025 common shares except where such purchases are made in accordance with "block purchases" exemptions under applicable TSX policies. MSL.TO: 1.46 (+0.04), MSLI: 1.28 (+0.03)
Merus Labs International Inc (MSLI) Downgraded From Hold to Sell
at The Street - Tue Oct 28, 8:46AM CDT
Merus Labs International Inc (MSLI) has been downgraded by TheStreet Ratings from Hold to Sell with a ratings score of D+.
MSLI: 1.28 (+0.03)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Oct 15, 11:47AM CDT
NPD: 1.38 (-0.03), IMDZ: 22.35 (-0.20), BCRX: 10.06 (+0.02), DLHC: 2.34 (-0.04), SWSH: 1.68 (-0.02), VSR: 2.99 (-0.03), PPHM: 1.48 (-0.01), EVRY: 0.76 (+0.03), DYNT: 3.81 (unch), NBG: 1.79 (-0.01), AMDA: 0.69 (-0.01), TRCH: 0.85 (-0.04), KTCC: 7.98 (-0.12), APT: 2.64 (-0.03), SHPG: 213.70 (-0.41), PENX: 18.90 (+0.01), LAKE: 10.79 (-0.40), MSLI: 1.28 (+0.03), COVS: 2.73 (unch)
Merus Labs Announces Management & Board Changes
Marketwire - Tue Sep 23, 6:31AM CDT
Merus Labs International Inc. ("Merus" or the "Company"
(TSX: MSL)(NASDAQ: MSLI) today announced that Mr. Elie Farah has resigned as CEO and as a member of the Merus Board to pursue other opportunities. The Board of Directors thanks Mr. Farah for his contribution to building a strong foundation and platform for growth for the Company and wishes him well in his future endeavors. MSLI: 1.28 (+0.03)
Merus Labs International (MSLI) Upgraded From Sell to Hold
at The Street - Tue Sep 16, 8:04AM CDT
Merus Labs International (MSLI) has been upgraded by TheStreet Ratings from Sell to Hold with a ratings score of C.
MSLI: 1.28 (+0.03)
IIROC Trade Resumption - MSL
CNW Group - Mon Sep 08, 7:44AM CDT
Trading resumes in:
MSLI: 1.28 (+0.03)
IIROC Trade Resumption - Merus Labs International Inc.
Newsfile Corp - Mon Sep 08, 7:38AM CDT
Trading resumes in:
MSLI: 1.28 (+0.03)
Merus Labs International Inc. Announces Acquisition of Sintrom(R)
Marketwire - Mon Sep 08, 7:32AM CDT
Merus Labs International Inc. ("Merus" or the "Company"
(TSX: MSL)(NASDAQ: MSLI) is pleased to announce that one of its wholly owned subsidiaries has acquired from Novartis AG ("Novartis" , in certain European countries, the rights to manufacture, market, and sell the branded prescription medicine product Sintrom(R) (acenocoumarol). Acenocoumarol is an anticoagulant indicated for the treatment and prevention of thromboembolic diseases. Sintrom(R) has been available in Europe for over 50 years and in calendar year 2013 the product had net sales of approximately US$28 million in the territories acquired. MSLI: 1.28 (+0.03), NVS: 93.52 (-0.82)
IIROC Trading Halt - MSL
CNW Group - Mon Sep 08, 7:17AM CDT
The following issues have been halted by IIROC:
MSLI: 1.28 (+0.03)
Merus Labs International Inc. Announces Completion of $7 Million Financing Transaction With Dacha Strategic Metals Inc.
Marketwire - Thu Aug 14, 2:29PM CDT
Merus Labs International Inc. ("Merus" or the "Company"
(TSX: MSL)(NASDAQ: MSLI) is pleased to announce that, further to its news release dated July 4, 2014, the Company has today completed the financing acquisition transaction with Dacha Strategic Metals Inc. ("Dacha" . The Company issued 4,246,544 common shares to Dacha in exchange for all of the issued and outstanding shares of a newly incorporated subsidiary ("Newco" incorporated by Dacha for the completion of the transaction. Newco held $6,975,001 in cash and had no other assets or liabilities upon completion of the Acquisition. MSLI: 1.28 (+0.03)
Merus Labs International Inc. Subsidiary Signs Product Acquisition Letter of Intent
Marketwire - Fri Aug 08, 5:16AM CDT
Merus Labs International Inc. ("Merus" or the "Company"
(TSX: MSL)(NASDAQ: MSLI) is pleased to announce today that one of its wholly owned subsidiaries has signed a letter of intent to acquire the rights to manufacture, market, and sell a branded prescription medicine product in certain European countries. The product is being divested by a large multinational pharmaceutical company. In the calendar year 2013, the product had net sales of approximately US$28 million in the applicable European territories. MSLI: 1.28 (+0.03)
Merus Labs International Inc. Announces Conversion of $10 Million Convertible Debentures
Marketwire - Thu Jul 17, 3:00PM CDT
Merus Labs International Inc. ("Merus" or the "Company"
(TSX: MSL)(NASDAQ: MSLI) is pleased to announce today that the Company has exercised its right to convert the $10 million unsecured convertible debentures (the "Convertible Debentures" issued to a large Canadian institutional investor in September 2013. The Company exercised its right based on the closing price of the Company's common shares having equalled or exceeded $2.30 per share for the 20 consecutive trading days ended July 14, 2014. In aggregate, the Company will issue 6,677,918 common shares to convert the outstanding $10 million principal amount plus accrued but unpaid interest. MSLI: 1.28 (+0.03)
Dacha releases audited financial statements for year ended March 31, 2014 and provides update on Merus transaction
CNW Group - Fri Jul 11, 3:15PM CDT
Dacha Strategic Metals Inc. (TSX-V: DSM) ("Dacha"
today released its audited consolidated financial results for the year ended March 31, 2014 and provided an update on its pending transaction involving Merus Labs International Inc. ("Merus" . For more information, please see Dacha's audited consolidated financial statements and management's discussion and analysis filed under Dacha's profile on SEDAR at www.sedar.com. Unless otherwise noted, dollar references below are to U.S. funds. DSM.VN: 0.185 (-0.010), MSLI: 1.28 (+0.03)
Merus Labs International Inc. Announces Closing of $10 Million Preferred Share Financing
Marketwire - Fri Jul 11, 3:01PM CDT
Merus Labs International Inc. ("Merus" or the "Company"
(TSX: MSL)(NASDAQ: MSLI) is pleased to announce today that the Company has completed its previously announced private placement issuance of $10 million of Series A convertible preferred shares (the "Series A Preferred Shares" to a large Canadian institutional investor. In aggregate, the Company issued 10,000 Series A Preferred Shares at a price of $1,000 per share for total proceeds of $10 million. The proceeds of the offering are expected to be used by the Company for future acquisition opportunities as well as for general corporate purposes. Additional details regarding the Series A Preferred Shares are provided in the Company's June 10, 2014 news release. MSLI: 1.28 (+0.03)
